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Acute myeloid leukemia (AML) is a disease 
with diverse genetic pathogenesis. More than 
140  recurrent  balanced  chromosomal  aber-
rations  have  been  described,  and  the  genes 
located at the chromosomal breakpoints have   
been identified for many of these aberrations. 
Additionally, >700 recurrent unbalanced ab-
errations  have  been  associated  with  AML, 
but only a few of the responsible genes have 
been delineated (Le Beau and Larson, 2000).   
In the present study, we aimed to address the 
mechanism by which an unbalanced chro-
mosomal  gain  might  cooperate  with  the 
t(15;17)  of  acute  promyelocytic  leukemia 
(PML; APL; a subtype of AML) to accelerate 
leukemogenesis.
The  t(15;17)-balanced  chromosomal  rear-
rangement juxtaposes the PML gene to the 
retinoic acid receptor  (RARA) gene, creating an 
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Gain of chromosome 8 is the most common chromosomal gain in human acute myeloid 
leukemia (AML). It has been hypothesized that gain of the MYC protooncogene is of  
central importance in trisomy 8, but the experimental data to support this are limited and 
controversial. In a mouse model of promyelocytic leukemia in which the MRP8 promoter 
drives expression of the PML-RARA fusion gene in myeloid cells, a Myc allele is gained in 
approximately two-thirds of cases as a result of trisomy for mouse chromosome 15.  
We used this model to test the idea that MYC underlies acquisition of trisomy in AML.  
We used a retroviral vector to drive expression of wild-type, hypermorphic, or hypomorphic 
MYC in bone marrow that expressed the PML-RARA transgene. MYC retroviruses  
cooperated in myeloid leukemogenesis and suppressed gain of chromosome 15. When the 
PML-RARA transgene was expressed in a Myc haploinsufficient background, we observed 
selection for increased copies of the wild-type Myc allele concomitant with leukemic 
transformation. In addition, we found that human myeloid leukemias with trisomy 8 have 
increased MYC. These data show that gain of MYC can contribute to the pathogenic effect 
of the most common trisomy of human AML.
© 2010 Jones et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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virus  (MSCV-MYC-IRES-GFP)  and  transplanted  them 
into lethally irradiated histocompatible mice (resulting an-
imals are referred to as PML-RAR + MYC mice). In par-
allel, we established control cohorts in which PML-RARA 
bone marrow was transduced with an empty mouse stem 
cell virus LTR-internal ribosomal entry site-GFP retrovi-
ral  vector  (MIG;  MSCV-IRES-GFP)  retrovirus  (PML-
RAR  +  MIG  mice)  and  control  FVB/n  marrow  was 
transduced with MYC retrovirus (control + MYC mice). 
Mice reconstituted with normal marrow cells transduced 
to express MYC became ill in a median of 90 d (Fig. 1 A). 
These control + MYC mice developed lymphoblastic dis-
ease, which presented as lymphomas involving the thymus 
with variable involvement of other tissues in seven mice 
and lymphomas of the orbit (site of injection of trans-
planted cells) in two mice. Representative pathology and 
an example of surface antigen expression are shown (Fig. 1, 
B and C). The disease was characterized by expression of 
T cell antigens, including CD90, CD3, variable CD4, and 
variable CD8. The blasts lacked cytoplasmic granules and 
were present in the thymus and other tissues. The time to ill-
ness appeared to be similar for recipients of PML-RAR + 
MYC cells (median time to illness 76 d, not statistically 
significantly decreased; Fig. 1 A), but the spectrum of dis-
ease was markedly different from that observed in the ab-
sence of PML-RAR. In contrast to the findings with 
MYC alone, eight of nine PML-RAR + MYC animals 
developed AML with numerous promyelocytes (hereafter 
referred to as APL). An example of surface antigen expres-
sion and representative pathology are shown (Fig. 1, C and D). 
The cells expressed variable levels of the Gr-1 and Mac-1 
myeloid antigens and the immature markers CD117 (Kit) 
and CD34. Leukemic blasts frequently contained numer-
ous primary granules, and there was uniform marked ex-
pansion of the spleen and infiltration of the liver. These 
leukemias were similar to those we have previously ob-
served in PML-RARA mice (Brown et al., 1997). One   
recipient animal in this PML-RAR + MYC group devel-
oped lymphoblastic disease, and in one recipient a thymic   
lymphoblastic lymphoma was present concomitant with 
APL. Some recipients of PML-RARA bone marrow trans-
duced with MIG became ill with long latency (median 
time to illness 274 d; Fig. 1 A), with findings similar to 
those  previously  observed  in  the  absence  of  retroviral 
transduction (Brown et al., 1997). These results demon-
strate that MYC accelerates the development of APL in 
PML-RARA mice.
MYC interacts with PML-RAR to impair  
myeloid maturation
To  investigate  the  impact  of  the  combination  of  PML-
RAR and MYC on myelopoiesis, we reconstituted mice 
with control or PML-RARA transgenic bone marrow that 
had been transduced with control (MIG) or MYC retroviral 
vectors. 5 wk after transplantation, the cohorts were euthanized, 
tissues were collected for histopathology, and GFP+ bone 
aberrant PML-RAR fusion protein. PML-RAR inhibits 
gene expression and disrupts PML nuclear bodies (Hong et al., 
1997; Grignani et al., 1998; Guidez et al., 1998; He et al., 
1998; Lin et al., 1998). Although APL is associated with the 
accumulation of undifferentiated myeloid cells, PML-RAR 
must cooperate with additional genetic lesions to fully block 
neutrophil maturation and promote leukemia. In APL, sec-
ondary karyotypic lesions are seen in 38% of cases, with tri-
somy 8 being the most common (12% of cases; Le Beau et al., 
2002). In fact, trisomy 8 is the most common unbalanced gain 
in AML in general (Grimwade et al., 1998).
In this study, we used a mouse model of APL in which the 
MRP8 promoter directs expression of the PML-RARA fusion 
gene in maturing myeloid progenitors, neutrophils, and mono-
cytes. Although PML-RAR expression initially causes mod-
est changes in neutrophil maturation, full progression to an 
APL-like disease requires additional mutations. We have pre-
viously shown that gain of mouse chromosome 15 (+m15) is 
the most common recurring abnormality (64% of cases) in our 
PML-RARA transgenic mice (Le Beau et al., 2002). This is 
consistent with the gain of chromosome 8 in human APL be-
cause m15 is syntenic to human bands 8q22-24.3. It has been 
difficult to identify genes that drive +h8/+m15. MYC/Myc, a 
candidate gene located in this region, has been implicated as a 
protooncogene in a wide array of human and mouse neoplasms 
and serves as a key regulator of cellular proliferation (Adhikary 
and Eilers, 2005). Small changes in MYC expression level have 
been shown to have significant phenotypic effects. For exam-
ple, there is a correlation between Myc expression and growth 
of mice, where substantial differences in growth are seen with 
less than twofold difference in gene expression (Trumpp et al., 
2001). Because MYC is required for normal hematopoietic dif-
ferentiation (Trumpp et al., 2001; Wilson et al., 2004), gain   
of an additional allele of MYC might have significant effects   
on myelopoiesis.
It has been speculated that MYC contributes to trisomy 8 
in AML; however, the importance of MYC copy number in 
AML pathogenesis is controversial. When overexpressed in 
mice, MYC can initiate the development of myeloid leuke-
mia (Felsher and Bishop, 1999a; Luo et al., 2005); however, 
MYC  transcripts  were  found  to  be  decreased  in  AMLs   
with trisomy 8 relative to normal CD34+ bone marrow cells 
(Virtaneva et al., 2001). Here, we show that MYC cooperates 
with PML-RAR in leukemic transformation and is an im-
portant driver of +15 in our APL mouse model. These data 
indicate a role for MYC gain in human myeloid neoplasia 
with trisomy 8.
RESULTS
MYC cooperates with PML-RAR to generate  
myeloid leukemia
We  hypothesized  that  MYC  is  an  important  driver  of 
chromosomal  gain  in  APL  and  that  it  cooperates  with 
PML-RAR to accelerate the development of leukemia. 
To assess this cooperativity, we transduced bone marrow 
cells from PML-RARA transgenic mice with MYC retro-JEM VOL. 207, November 22, 2010 
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The tissues of the recipient animals in the four groups 
were also examined 5 wk after transplantation. The bone 
marrow, spleens, and livers of the Control + Control, Con-
trol + MYC, and PML-RAR + Control groups were   
essentially normal (Fig. S1). In contrast, at 5 wk after trans-
plantation abnormalities were already apparent in the PML-
RAR + MYC recipients. In the spleens, there were not only 
areas of normal-appearing red pulp with mixed myeloid cell 
populations but also areas effaced by myeloid cells (Fig. S1; 
compare two insets of PML-RAR + MYC spleen). In the 
livers, modest spread of myeloid cells was apparent.
A  strong  cooperative  interaction  of  PML-RAR  and 
MYC was seen at 5 wk, but the APLs we observed in mori-
bund animals after 8–13 wk may have reflected progression 
from an initiated state rather than the simple expansion of 
cells co-expressing PML-RAR and MYC. Morphological 
marrow cells were analyzed by flow cytometric immuno-
phenotyping  and  sorted  for  morphological  examination.   
As compared with the other three groups, the combination 
of PML-RAR and MYC strongly inhibited the morpho-
logical maturation of myeloid cells (Fig. 2, A and B). The 
MRP8 PML-RARA transgene had been previously shown 
to decrease the expression of the Gr-1 myeloid differentia-
tion antigen in preleukemic mice (Brown et al., 1997).   
We found that PML-RAR was also associated with an in-
crease in cells expressing the immature CD34 marker. The 
combination of PML-RAR and MYC caused a statisti-
cally significant shift toward an immature immunopheno-
type compared with the effects of PML-RAR or MYC 
alone (Fig. 2, C and D). In short, morphological and flow 
cytometric analyses showed that PML-RAR and MYC 
cooperated to impair myeloid cell maturation.
Figure 1.  MYC cooperates with PML-
RAR to induce AML. (A) Bone marrow of 
PML-RARA mice (PR) was transduced with a 
retrovirus encoding MYC and GFP (MYC) or 
control retrovirus encoding GFP only (MIG) and 
introduced into lethally irradiated recipient 
mice. Combined results from two independent 
experiments for each group are shown. Median 
time to AML of 8 PML-RAR + MYC mice was 
75 d (1 additional mouse developed T cell acute 
lymphoblastic leukemia/lymphoma (T-ALL) at 
92 d; overall median time to illness 76 d). With 
longer latencies, some PML-RAR + MIG con-
trol retrovirus mice developed leukemia (four 
mice developed AML, one mouse developed  
T-ALL, and four mice were euthanized without 
leukemia or lymphoma). Control FVB/n (Cntr) + 
MYC mice developed lymphomas with a me-
dian latency of 90 d (7 mice developed T-ALL, 2 
mice developed lymphoblastic lymphoma in 
the orbit (injection site), and 1 mouse was 
euthanized without evidence of leukemia or 
lymphoma). Differences in leukemia-free sur-
vival: PR+MIG versus PR+MYC, P < 0.0001; 
PR+MYC versus Cntr+MYC, P = NS. (B) Pathol-
ogy of Cntr + Myc mouse. Results representa-
tive of nine lymphomas are shown. (i) Cytology 
of lymphoblastic cells from the lymph node of 
mouse #609. Histology of (ii) bone marrow of 
mouse #34, (iii) thymus of mouse #33, and  
(iv) liver of mouse #32. (i) Wright’s Giemsa 
stain. (ii-iv) H&E stain. Bars: (i) 8 µm; (ii) 12 µm; 
(iii and iv) 60 µm; (iii inset) 24 µm. (C) Immuno-
phenotype of lymphoblastic lymphoma and 
APL. Splenocytes from a Control + MYC mouse 
(left; #609) and from a PML-RAR + MYC 
mouse (right; #608) were stained with the 
indicated antibodies. Plots are gated on GFP+ 
cells. Results representative of nine lymphomas 
and eight leukemias are shown. (D) Pathology of PML-RAR + MYC mouse. Results representative of eight leukemias are shown. (i) Cytology of leukemic cells 
from spleen of mouse #586. Pathology of (ii) bone marrow of mouse #478, (iii) spleen of mouse #478, and (iv) liver of mouse #478. (i) Wright’s Giemsa stain. 
(ii-iv) H&E stain. Bars: (i) 8 µm; (ii) 12 µm; (iii and iv) 60 µm; (iii inset) 24 µm.2584 Gain of MYC underlies recurrent trisomy in APL | Jones et al.
reported  to  decrease  MYC-induced  apoptosis  (Hemann   
et al., 2005). MYCMBII, exemplifying a hypomorphic allele, 
has a deletion of aa 124–149 (MYC-box II), the deletion of 
which has been associated with loss of repression of some 
MYC target genes as well as decreased transforming activity 
(Stone et al., 1987; Freytag et al., 1990; Penn et al., 1990; Li 
et al., 1994; Herbst et al., 2005). Co-expression of PML-
RAR with MYCT58A cooperated to induce myeloid leuke-
mias in recipient animals (Fig. 3 A). The leukemias were 
morphologically  similar  to  those  observed  in  mice  co- 
expressing PML-RAR and wild-type MYC (Fig. S2 A). 
Median time to illness of 70 d for PML-RAR + MYCT58A 
mice was slightly shorter than the 76-d median observed in 
mice expressing PML-RAR + MYC (Fig. 1 A; P < 0.01). 
Co-expression  of  PML-RAR  with  MYCMBII  similarly 
showed cooperation in APL induction (Fig. 3 B and Fig. S2 B), 
with median time to illness of 92 d appearing modestly lon-
ger than seen with wild-type MYC (Fig. 1 A; P = 0.05). 
Hence, latency to disease correlated with MYC allele strength. 
Recipients of control bone marrow transduced with MYCT58A 
developed myeloid leukemia and lymphoblastic disease with 
latencies (median 101 d) similar to those seen in control + 
MYC mice (Fig. 1 A; P = NS), but longer than for PML-RARA 
marrow transduced with MYCT58A (Fig. 3 A; P < 0.0001), 
whereas a subset of recipients of control bone marrow trans-
duced with MYCMBII developed lymphoblastic disease with 
observations  provided  support  for  this  possibility.  In  fully   
developed APL (Fig. 1 D, i), the leukemic cells showed little 
evidence of maturation beyond the promyelocyte stage, with 
mostly oval or indented nuclei, open chromatin, and many 
cells with primary granules. In contrast, the PML-RAR + 
MYC cells at 5 wk (Fig. 2 A) showed a variable morphology, 
including more cells with differentiation beyond the promy-
elocyte stage. In fully developed APL, the bone marrow and 
spleen were effaced by immature cells with predominantly 
round to oval nuclei (Fig. 1 D, ii and iii), whereas the bone 
marrow and spleen of PML-RAR + MYC cells at 5 wk 
showed  a  more  heterogeneous  myeloid  cell  population   
(Fig. S1). Collectively, the morphological findings suggested 
that PML-RAR and MYC strongly initiate, but may not 
complete, the process of leukemogenesis.
MYC mutants provide further evidence of cooperation 
between increased MYC and PML-RAR in myeloid 
leukemogenesis
To further evaluate the role of MYC in APL pathogenesis, 
we introduced two mutant versions of MYC (MYCT58A and 
MYCMBII) into PML-RARA bone marrow and assessed the 
effect on leukemic transformation. MYCT58A, exemplifying a 
hypermorphic allele, contains an alanine substitution at thre-
onine 58 blocking phosphorylation that increases MYC pro-
tein stability (Sears et al., 2000). This mutation has also been 
Figure 2.  PML-RAR and MYC cooper-
ate to alter myeloid maturation. (A) Con-
trol (Cntr) or PML-RARA (PR) transgenic bone 
marrow was transduced with MIG (Cntr) or 
MYC retroviruses, and lethally irradiated mice 
were reconstituted with this bone marrow.  
5 wk after transplantation, mice were eutha-
nized and GFP+ cells were sorted from bone 
marrow and stained with Wright’s Giemsa 
stain. Results are representative of three to 
four animals per group. Bars, 8 µm. Each 
panel is comprised of two images of equal 
size, showing two different microscopic fields. 
L, Lymphocyte. (B) GFP+ bone marrow cells 
were stained as in A. 200 cell differential 
counts were performed. Percentages of cell 
types within the myeloid compartment are 
shown. Immat, Immature forms (blasts and 
promyelocytes); Intermed, myeloid intermedi-
ate forms; Neut, neutrophils; Mono, mono-
cytes; Eos, eosinophils; n: Cntr+Cntr = 4; 
Cntr+MYC = 3; PR+Cntr = 4; PR+MYC = 3. 
Mice in each group were generated in single 
experiments. Means ± SD are shown. Differ-
ences in the percentages of intermediate 
forms and/or neutrophils were statistically significant for all comparisons except Cntr+Cntr versus Cntr+MYC. PR+MYC data for mature neutrophils dif-
fers from other three groups: PR+MYC versus Cntr+Cntr, P < 0.0001; PR+MYC versus Cntr+MYC, P < 0.01; PR+MYC versus PR+Cntr, P < 0.02. (C) Bone 
marrow cells from mice described in A were stained as described in Materials and methods. 34,000 GFP+ cells negative for lymphoid and erythroid anti-
gens were analyzed for Gr-1 and CD34. Gr-1 and CD34 fluorescence histograms representative of three mice per group are shown. (D) Gr-1 and CD34 
levels were analyzed in C. All values were normalized to Cntr+Cntr. Means ± SD are shown. n = 3 in each group. Mice in each group were generated in 
single experiments. *, P < .05; **, P < .01 for comparison to Cntr+Cntr; #, P < 0.05 PR+MYC versus PR+Cntr and P < 0.01 PR+MYC versus Cntr+MYC;  
##, P < 0.01 PR+MYC versus Cntr+MYC.JEM VOL. 207, November 22, 2010 
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studied at 5– 6 wk after transplantation. These alleles also   
cooperated with PML-RAR to impair myeloid maturation 
(Fig.  S2,  C  and  D,  and  unpublished  data).  Interestingly, 
splenic and liver pathology differed at 5 wk between the two 
alleles, with greater evidence of progression in recipients of 
PML-RAR + MYCT58A than in recipients of PML-RAR + 
MYCMBII;  areas  of  myeloid  expansion  were  seen  in  the 
PML-RAR + MYCT58A spleens accompanied by myeloid 
infiltrates in their livers (Fig. S2 E).
Protein levels and studies of clonality also suggest interplay 
between MYC allele strength and myeloid transformation
We performed Western blotting for MYC using an anti-
serum that recognizes both human and mouse MYC protein 
(Chiariello et al., 2001; Teng et al., 2004). Representative 
data are shown in Fig. 4 A, and quantification of data from 
normal bone marrow and from leukemic bone marrow   
of PML-RAR + MYCT58A, PML-RAR + MYC, and 
PML-RAR + MYCMBII mice is shown in Fig. 4 B. These 
data indicate that the retroviral constructs result in MYC 
overexpression at levels up to threefold of that present in nor-
mal marrow cells.
longer  latency  and  incomplete  penetrance  (leukemia-free 
survival: PML-RAR + MYCMBII vs. control + MYCMBII, 
P < 0.0001; control + MYC vs. control + MYCMBII,   
P = 0.0001; Fig. 1 A and Fig. 3 B). The observation that the 
hypomorphic MYCMBII allele was only weakly oncogenic 
in the absence of PML-RAR, but induced APL with com-
plete penetrance in the presence of PML-RAR, is note-
worthy. This finding shows that a weakly transforming genetic 
change may nevertheless contribute to acute leukemia in the 
presence of cooperating genetic events.
Recipients  of  PML-RAR  +  MYCT58A  and  PML-
RAR + MYCMBII bone marrow, as well as recipients of 
control + MYCT58A and control + MYCMBII, were also 
Figure 3.  MYC mutants cooperate with PML-RAR to induce AML. 
(A) Bone marrow of PML-RARA (PR) or control FVB/n (Cntr) mice was trans-
duced with a retrovirus encoding MYCT58A and introduced into lethally  
irradiated recipient mice. Combined results from two independent  
experiments for each group are shown. Median time to APL of 10 PML-
RAR + MYCT58A mice was 70 d. Control FVB/n + MYCT58A mice developed 
AML (5 mice), T-ALL (3 mice), or were euthanized without evidence of leuke-
mia or lymphoma (2 mice). Median time to disease was 101 d. Difference in 
leukemia-free survival: P < 0.0001. (B) Bone marrow of PML-RARA (PR) or 
control FVB/n (Cntr) mice was transduced with a retrovirus encoding MYC 
with a deletion of the MBII domain (MYCMBII) and introduced into lethally 
irradiated recipient mice. Combined results from two independent experi-
ments for each group are shown. Median time to APL of 10 PML-RAR + 
MYCMBII mice was 92 d. Control FVB/n + MYCMBII mice developed T-ALL 
(four mice) or were euthanized without evidence of leukemia or lymphoma 
(six mice). Difference in leukemia-free survival: P < 0.0001.
Figure 4.  MYC protein levels in PML-RAR + MYC or MYC mu-
tant leukemias. (A) Whole-cell lysates from normal bone marrow (Cntr) 
and PML-RAR + MYC, MYCT58A, or MYCMBII leukemic cells were probed 
with anti-MYC. The same blot was stripped and reprobed with anti– 
-actin antibody for loading control. Cell lysates of FDC-P1 cells and 
FDC-P1 transduced with MYC are also shown. (B) Optical density of MYC 
protein was normalized to -actin and shown as the percentage of MYC 
level in normal bone marrow (Cntr). Means ± SD are shown. n = 3 in each 
group. Normal bone marrows were from three normal FVB/n mice.  
Leukemic samples were from nine independent APLs arising from the 
survival experiments shown in Figs. 1 A, 3 A, and 3 B. Data were obtained 
from two independent immunoblots; each sample was analyzed once.  
*, P < .05; **, P < .01 for comparison to normal Cntr bone marrow.2586 Gain of MYC underlies recurrent trisomy in APL | Jones et al.
This frequency of 5% is markedly less than the 60% frequency 
of trisomy 15 in PML-RAR leukemias that arose in the   
absence of MYC retroviruses (Table S4; P < 0.00001). Fur-
thermore, the data observed in PML-RAR + MYCMBII 
leukemias indicated that the decrease in trisomy 15 was an 
effect of MYC expression: 80% of these leukemias showed 
clonal karyotypic abnormalities, but none showed the com-
mon gain of 15 seen when MYC was not introduced. These 
findings suggest that when MYC is overexpressed there is re-
lief of selective pressure to gain chromosome 15, supporting 
our hypothesis that Myc contributes to this gain. The findings 
in the hypomorphic MYCMBII leukemias also demonstrate 
that allele strength influences the likelihood of karyotypic 
changes accompanying progression to leukemia.
Gain of Myc is selected for in a mouse model of APL
To further assess the importance of Myc gain, we generated 
PML-RARA  mice  that  were  haploinsufficient  for  Myc 
(PR+Myc+/) by crossing PML-RARA transgenic mice to 
mice that had the open reading frame of one Myc allele re-
placed with a Pgk-hprt minigene (Trumpp et al., 2001). Bone 
marrow was harvested from the resulting PR+Myc+/ mice 
and transplanted into lethally irradiated FVB/n recipients. 
The results were compared with mice transplanted with 
PML-RARA bone marrow expressing two wild-type Myc al-
leles (PR+Myc+/+). Bone marrow haploinsufficient for Myc 
had decreased ability to contribute to long-term repopulation 
as compared with bone marrow with two copies of Myc.   
Peripheral blood granulocytes were assessed for CD45.1 (do-
nor) and CD45.2 (recipient) 3 mo after lethal irradiation and 
reconstitution. Continued contribution to myeloid cells is a 
marker of persistence of transplanted cells within the stem 
cell compartment. Results were similar whether or not the 
PML-RARA transgene was present. Recipients of Myc+/ 
bone marrow cells (n = 7) showed a mean of 37% donor 
Two approaches were used to assess the clonality of leu-
kemias arising in mice expressing any of the three MYC al-
leles: cytogenetic analysis, including Southern blotting for 
retroviral integration sites, and spectral karyotyping. South-
ern  blotting  was  performed  on  PML-RAR  +  MYC, 
PML-RAR + MYCT58A, and PML-RAR + MYCMBII 
leukemias and on bone marrow from PML-RAR + MYC 
mice 5 wk after transplantation, a retrovirally marked leuke-
mia that arose in a PML-RAR + MIG mouse, and a retro-
virally  marked  lymphoblastic  lymphoma  that  arose  in  a 
Control + MYC mouse. Results are shown in Fig. 5. Retro-
viral integration patterns ranged from single-dominant bands 
in the PML-RAR + MIG (#6869) and Control + MYC 
(#34) mice to a pattern consistent with multiclonal integra-
tion (multiple low-intensity restriction fragments) in most 
PML-RAR + MYC mice at 5 wk (i.e., #547 and 548).   
In one PML-RAR + MYC mouse at 5 wk (#546), a domi-
nant clone (or clones) was already present, and the fully de-
veloped  leukemias  showed  integration  patterns  that  were 
consistent with oligo- to monoclonal disease. These data re-
vealed that recipients of PML-RAR + MYC bone marrow 
initially had multiple retrovirally marked clones in their mar-
row, and that one or a few clones arose within these mixed 
populations to achieve dominance by the time mice were 
outwardly ill. The low clonality observed by Southern blot 
suggested that the leukemias arose from only a few of the 
cells that expressed PML-RAR and MYC.
To  further  assess  leukemia  clonality  and  examine  the   
impact of MYC expression on cytogenetic changes, spectral 
karyotyping was also performed. Tables S1–S3 present the 
results of cytogenetic studies in 8 PML-RAR + MYC leu-
kemias, 4 PML-RAR + MYCT58A leukemias, and 10 PML-
RAR + MYCMBII leukemias. A striking finding is that a 
gain of chromosome 15 was observed in only 1 of the 22 leu-
kemias with retroviral vector expression of MYC or a variant. 
Figure 5.  Southern blot of PML-RAR + 
MYC leukemias shows clonal retroviral 
integrations. Genomic DNA samples were 
digested with EcoRI, which cuts within the 
multicloning site of retroviral integrants, and 
the blot was probed with a probe hybridizing 
to GFP sequences. 6989, A GFP+ leukemia that 
arose in a PML-RAR + MIG recipient mouse. 
34, A GFP+ lymphoblastic lymphoma that 
arose in a recipient of Control + MYC- 
transduced bone marrow. PR+MYC Pre,  
preleukemic bone marrow from PML-RAR + 
MYC mice 5 wk after transplantation. 
PR+MYC, PR+MYCMBII, and PR+MYCT58A, 
leukemias that arose from recipients of PML-
RAR bone marrow transduced with various 
MYC alleles. Data in this figure were obtained 
in three independent Southern blots. Thick 
vertical lines separate groups of samples and 
indicate juxtapositions of lanes. Thin vertical 
lines also indicate juxtaposition of lanes.JEM VOL. 207, November 22, 2010 
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granulocytes at 3 mo as compared with a mean of 83% in   
recipients of Myc+/+ bone marrow (n = 5; P < 0.001). In ac-
cord with the decreased repopulating ability of Myc haploin-
sufficient bone marrow, haploinsufficiency for Myc delayed 
the development of leukemia; median latency to disease   
was 339 d for PR+Myc+/ mice and 258 d for PR+Myc+/+ 
(Fig. 6 A). Two thirds of PR+Myc+/+ deaths were from leu-
kemia, whereas only 31% of animals in the cohort haploin-
sufficient  for  Myc  died  from  leukemia.  The  cytology  and 
histopathology of leukemia arising from PR+Myc+/ bone 
marrow is shown in Fig. 6 B. These results indicate that mice 
transplanted with PML-RARA bone marrow haploinsuffi-
cient for Myc developed APL with decreased penetrance and 
increased latency.
To directly test our hypothesis that Myc is an important 
driver of +8/+15 in APL, we assessed whether there was a 
gain of chromosome 15 and Myc copy number in leukemias 
that arose from PR+Myc+/ mice. We performed quantita-
tive PCR (Q-PCR) analysis on genomic DNA isolated from 
these leukemias to determine Myc and Pgk-hprt copy number 
and compared the results with cytogenetic analysis on the 
same samples. We first analyzed previously characterized mu-
rine leukemias 1111 and 1127 as controls for internal consis-
tency between these methodologies. Leukemia 1111 contains 
an extra copy of chromosome 15, but leukemia 1127 does 
not.  As  expected,  the  number  of  wild-type  Myc  alleles   
was equal to the copy number of chromosome 15, and no 
Pgk-hprt (representing the null allele) was detected (Fig. 6 C).
We then analyzed six PR+Myc+/ leukemias by karyo-
typing and using Q-PCR to determine Myc and Pgk-hprt 
copy number. One PR+Myc+/ leukemia (#3257) showed 
neither gain of chromosome 15 nor gain of the wild-type 
Myc allele, whereas four leukemias analyzed with both tech-
niques had +15 and showed gain of a Myc allele (Fig. 6 C and 
Table I). In one of these samples (#6748), all three copies of 
chromosome 15 appeared to have the wild-type Myc allele, 
suggesting that the Myc-null allele was replaced. Interestingly, 
analysis  of  one  additional  PR+Myc+/  leukemia  that  did   
not gain chromosome 15 showed four copies of the Myc  
allele and no Pgk-hprt allele by Q-PCR (#836; Table I; not 
Figure 6.  Haploinsufficiency for Myc delays leukemia develop-
ment. (A) Bone marrows of PML-RARA Myc+/+ or PML-RARA Myc+/ FVB/
n mice were harvested and transplanted into lethally irradiated FVB/n 
recipient animals. Combined results from eight (Myc+/+) or eleven (Myc+/) 
independent transplantation experiments are shown. Mice were followed 
for the development of leukemia. Nonleukemic deaths were censored at 
the time of death. 67% of PML-RARA Myc+/+ deaths were from leukemia, 
whereas 31% of PML-RARA Myc+/ recipient mice died of leukemia. Me-
dian latency among leukemic animals was 258 d for Myc+/+ and 339 d for 
Myc+/. P < 0.0001. (B) Morphology of leukemias arising in PML-RARA 
Myc+/ mice. Results representative of 16 leukemias are shown. (i) Cytology 
of leukemic cells from spleen of mouse #836. L, Lymphocyte. Histology of 
(ii) bone marrow of mouse #828, (iii) spleen of mouse #828, and (iv) liver 
of mouse #828. (i) Wright’s Giemsa stain. (ii-iv) H&E stain. Bars: (i) 8 µm; 
(ii) 12 µm; (iii and iv) 60 µm; (iii inset) 24 µm. (C) Gain of chromosome 15 
and the wild-type Myc allele in PML-RARA Myc+/ leukemias. The number 
of copies of chromosome 15 as determined by cytogenetic analysis is 
indicated for each sample; 2 previously characterized leukemias (#1111 
and #1127), 5 PR+Myc+/ leukemias, and 1 nonleukemic PR+Myc+/ mar-
row. Copy numbers for the wild-type Myc and Pgk-hprt alleles are also 
given for the same samples. Samples were run in triplicate in one to eight 
independent experiments. Pgk-hprt copy number could not be determined 
for leukemia #5727 because of insufficient quantity of DNA. *, Pgk-hprt 
copy number values are 0. Results for leukemia #836 showing no gain of 
chromosome 15, but increased copy-number for the wild-type Myc allele, 
are not shown here, but are included in Table I and discussed in the text.
 2588 Gain of MYC underlies recurrent trisomy in APL | Jones et al.
that +15 is suppressed when MYC is expressed by retroviral 
transfer, demonstrate that Myc is an important driver of +15 
in APL.
Increased MYC is seen in human APL
Payton  et  al.  (2009)  performed  gene  expression  of  14   
human APL samples and of 5 samples of normal human 
promyelocytes  using  Affymetrix  Human  Genome  U133 
Plus 2.0 Arrays. Normalized signals for MYC transcript lev-
els were obtained from Gene Expression Omnibus Dataset 
Series GSE12662. Mean MYC transcript levels (normalized 
within this study) were 2713 (SD, 1092; range, 1513–3911) 
for normal human promyelocytes and 31247 (SD, 21624; 
range, 5615–81602) for human APL (P < 0.001). This in-
crease in MYC was seen in all samples: 11 cases with t(15;17) 
as the only karyotypic lesion, 2 cases with t(15;17) and +8, 
and 1 case with a complex karyotype (Fig. S3 A). Hence, 
increased MYC is a general feature of human APL. We fur-
ther sought to ascertain whether APL with trisomy 8 had 
increased MYC levels relative to APL with only the t(15;17). 
Published literature and the GEO database were searched 
for available expression data on human APL with and with-
out trisomy 8. Two additional datasets were identified (Ross 
et al., 2004; Verhaak et al., 2009) for which both karyotypic 
and expression data were available. However, small sample 
size  (40  APLs  with  t(15;17)  and  5  APLs  with  t(15;17)   
and +8) and variation within each group led to an incon-
clusive analysis.
depicted  in  Fig.  6  C).  Fluorescence  in  situ  hybridization   
using a Myc probe demonstrated that only two Myc signals 
were present in this leukemia. This finding suggests the pres-
ence of a cytogenetically undetectable duplication event of 
the wild-type Myc allele on both copies of chromosome 15, 
or a local amplification event, resulting in three tandem copies 
of Myc on a single homologue.
We  analyzed  seven  additional  leukemias  from  the 
PR+Myc+/ cohort by either karyotyping or Q-PCR and 
found that four of them showed +15 or gain of a Myc allele 
(Table I). Four additional animals that died from causes un-
related to leukemia showed no increase in Myc copy num-
ber (Table I and one example shown in Fig. 6 C). Altogether, 
Q-PCR data and karyotypes indicated that there is selective 
pressure to gain Myc with transformation: although an in-
crease in Myc gene-dosage was not obligatory, by one or 
both  methods  Myc  copy-number  was  increased  in  9–13 
PR+Myc+/ leukemias analyzed. The wild-type Myc allele 
was gained in 8 of 11 samples studied by Q-PCR (in 6 leu-
kemias two wild-type Myc copies were restored; in 2 leuke-
mias wild-type Myc copy number was increased to 3 or 4), 
the  Myc-null  allele  was  lost  in  4  of  9  cases  for  which   
Q-PCR data could be obtained, and we observed gain of 
mouse chromosome 15 in 5 of 8 samples studied karyotypi-
cally. In the three cases with +15 for which the identity of 
the gained chromosome could be definitively ascertained, 
Q-PCR results indicated gain of the chromosome encoding 
wild-type Myc. These results, in conjunction with our finding 
Table I.  Q-PCR and karyotypic analyses of PR+Myc+/ mice
Mouse Diagnosis Myc alleles Pgk-hprt alleles Karyotype
3257 Leukemic 1 1 40,XY,der(14)t(6;14)(B1;E)[7]/42,XY,+6,+8[2]/42,XY,+X,+6[1]/ 
41,XY,+12[1]/40,XY[1]
5270 Leukemic 2 1 42,X,-Y,+8,+10,+15[7]/42,idem,+1,del(1)(A2F),-11[1]/ 
42,X,+X,-Y,+8,+10[1]/40,XY[1]
5457 Leukemic 2 1 44,XX,+6,+8,+10,+15[1]/43,idem,-X[9]/40,XX[1]
5727 Leukemic 2 Not determined 42,X,-X or -Y,+8,+10,+15[2]/43,idem,+7[7] 
48,idem,+2,+6,+7,+7,+10,+16[1]
6748 Leukemic 3 0 45,XY,+8,+10,+12,+15,+17[5]/46,idem,+14[4]/ 
42,XY,t(2;12)(H1;F1),-8,+10,+13,+15[1]
836 Leukemic 4 0 40,XX,del(2)(DH3)[5]/41,idem,+8[4]/40,XX[1]
5287 Leukemic 2 Not determined Not obtained
838 Leukemic 2 0 Not obtained
829 Leukemic 2 0 Not obtained
274 Leukemic 1 1 Not obtained
2652 Leukemic 1 1 Not obtained
1892 Leukemic Not determined Not determined 40,X,-Xor-Y,+der(18)t(1;18)(B;E3)[1]/44,idem,dup(4)(A2C4), 
der(5;11)(A1;A1),+8,+10,+12,+15,+16,+17,-18[9]
6675 Leukemic Not determined Not determined 43,XY,+7,+8,+10[10]
1904 Nonleukemic 1 1 40,XX[6]/40,XY[2]/41,XX,+15[1]/39,XX,del(1)(BD),-9,-19,+mar1[1]
643 Nonleukemic 1 1 Not obtained
6514 Nonleukemic 1 1 Not obtained
2651 Nonleukemic 1 1 Not obtained
Clonal gains of chromosome 15 are indicated in bold.JEM VOL. 207, November 22, 2010 
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Gilliland and Tallman, 2002). An alternate conceptual model 
of leukemia holds that individual genetic changes do not fall 
neatly into two classes of mutation with linear relationships to 
cellular phenotypes (i.e., increased survival, enhanced prolif-
eration, and arrested differentiation). Rather, in this view,   
it is the interaction of genetic changes that cumulatively gen-
erate the leukemic phenotype. Changes wrought by copy 
number increase appear more compatible with the alternate 
model, and our findings support this conception.
Our studies of PR+Myc+/, PR+Myc+/+, PML-RARA + 
MYCMBII,  PML-RARA  +  MYC,  and  PML-RARA  + 
MYCT58A mice suggest that as MYC expression is increased, 
the latency to leukemia decreases (Table II). This indicates 
that as MYC levels increase either fewer additional events are 
needed to complete transformation or the likelihood of addi-
tional cooperating events increases, or both. Because in the 
same series of PML-RAR mice the karyotypic complexity 
of the leukemias was low when MYC and MYCT58A were 
overexpressed (Table II), our data are most consistent with 
the hypothesis that at high levels of MYC fewer changes are 
needed. We further note that although in some settings de-
regulated MYC is associated with chromosomal instability, 
which may contribute to cancer development (McCormack 
et al., 1998; Felsher and Bishop, 1999b; Sargent et al., 1999; 
Barna et al., 2008), karyotypic complexity was inversely cor-
related with initial MYC level in our model. This finding 
supports the concept that the contribution of chromosomal 
instability to MYC-mediated transformation is context de-
pendent (Wade and Wahl, 2006).
Although not definitive, our data suggest that the combina-
tion of PML-RAR and MYC is not sufficient to complete 
MYC transcripts appear elevated in human AML  
with trisomy 8
In an effort to determine whether MYC levels are propor-
tionally increased by gain of chromosome 8, we expanded 
our  analysis  to  compare  MYC  transcript  levels  in  normal 
karyotype AML as compared with AML with +8. For this 
purpose we used a large dataset from the Gene Expression 
Omnibus  Dataset  Series  GSE6891  (Verhaak  et  al.,  2009).   
In this dataset, MYC levels from 189 normal karyotype AMLs 
and 20 AMLs with +8 were available. Mean MYC levels in 
AML with +8 (normalized within this study) were 1256 (SD, 
879; range, 139–2637), whereas for normal karyotype AML 
average levels were 866 (SD, 699; range, 82–3812). Hence, 
MYC levels with gain of a third chromosome encoding MYC 
averaged 45% higher than when only two MYC chromosomes 
were present. This value is close to what would be predicted   
if each chromosome were equally active. Even with the vari-
ability within each group, this difference reached statistical 
significance (P = 0.03; Fig. S3 B).
DISCUSSION
In this study, we demonstrate that MYC cooperates with 
PML-RAR to accelerate the development of myeloid leu-
kemia and that gain of Myc is a driver mutation in gain of the 
chromosome on which MYC is encoded (i.e., MYC/Myc 
gain is selected for). One conceptual model of the genetic 
pathogenesis  of  AML  holds  that  mutations  of  two  classes   
cooperate to generate disease; i.e., mutations that enhance 
proliferation and/or survival but do not affect differentiation 
collaborate with mutations that impair differentiation and may 
expand progenitors (Graf and Beug, 1983; Beug et al., 1985;   
Table II.  Characteristics of leukemias initiated by the cooperation of PML-RAR and MYC
Characteristics PR+Myc+/ PR+Myc+/+ PR+MYCMBII PR+MYC PR+MYCT58A
Myeloid Leukemia (%) 31 67 100 89 100
Median Latency (d) 339 258 92 76 70
SKY analysis
  No. cases 8 15 10 8 4
  Clonal abnormality (%) 8 (100) 14 (93) 8 (80) 1 (13) 1 (25)
Karyotype Complexity Complex Intermediate Simple Simple Simple
Recurring clonal abnormalities (%)
  2 or del(2) 1 (13) 1 (7) 0 (0) 0 (0) 0 (0)
  +4 or dup(4) 1 (13) 2 (13) 0 (0) 0 (0) 0 (0)
  +6 2 (25) 2 (13) 0 (0) 0 (0) 0 (0)
  +7 2 (25) 1 (7) 0 (0) 0 (0) 0 (0)
  +8 8 (100) 7 (47) 0 (0) 0 (0) 0 (0)
  +10 6 (75) 5 (33) 5 (50) 0 (0) 0 (0)
  +12 2 (25) 0 (0) 0 (0) 0 (0) 0 (0)
  +14 1 (13) 4 (27) 0 (0) 0 (0) 0 (0)
  +15 5 (63) 9 (60) 0 (0) 1 (13) 0 (0)
  +16 1 (13) 5 (33) 0 (0) 0 (0) 0 (0)
  +17 2 (25) 2 (13) 0 (0) 0 (0) 0 (0)
  +18 or partial trisomy 1 (13) 2 (13) 0 (0) 0 (0) 0 (0)
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Schnittger et al., 2002). The identification of other changes 
that cause increased MYC in human leukemic promyelocytes 
awaits additional studies.
A previous study on MYC levels in human AMLs with 
+8 had noted decreased MYC in +8 AML as compared with 
normal human CD34+ bone marrow cells, and had thereby 
implied that MYC might not be increased by gain of chro-
mosome 8 (Virtaneva et al., 2001). However, the number of 
samples in this earlier study was low: 7 normal samples were 
compared with 10 normal karyotype AMLs and with 10 AMLs 
with trisomy 8. We examined a large publically available   
dataset (Verhaak et al., 2009) and observed that, on average, 
MYC levels were proportionately increased in the pres-
ence of trisomy 8. The large dataset permitted this finding to 
emerge despite the heterogeneity of MYC mRNA levels in 
human AML.
Although our data reveal a strong correlation between 
MYC dose and leukemic transformation, the notion that gain 
of the MYC protooncogene is of central importance in tri-
somy 8 was controversial. A study of AML with amplifica-
tions of 8q24 suggested that another gene located near MYC 
in this region, TRIB1, is the target of gene amplification. 
This suggestion was based on the finding that TRIB1 was 
overexpressed, whereas MYC RNA could not be detected 
(Storlazzi et al., 2006). Further substantiating its role, Trib1 
was identified as a common insertion site in leukemias in-
duced by Hoxa9/Meis1 retroviruses (Jin et al., 2007), and 
both MYC and TRIB1 can be co-overexpressed in AML 
patients (Röthlisberger et al., 2007). Although the present 
study does not address the role of TRIB1 in APL, it is possi-
ble that MYC and TRIB1 cooperate in the disease process. 
PVT1 is yet another nearby locus on human chromosome 8 
that has been implicated in oncogenic transformation (Guan 
et al., 2007). Recent studies examined chromosome copy 
number changes at high resolution in a large spectrum of   
human cancer cell lines and tumor tissues including myeloid 
disorders (Beroukhim et al., 2010; Bignell et al., 2010). These 
studies  revealed  that  the  MYC  containing  chromosome   
region is among the most frequently gained chromosomal   
regions and that the MYC gene was specifically contained 
within the peak of regional gain. These data further support 
the notion that gain of MYC is important for pathogenic ef-
fects of gaining this portion of chromosome 8. Additional 
studies examined copy number alterations in APL and found 
that gains of distal 8q included MYC in all cases where this 
region was gained (Akagi, et al. 2009; Radtke, et al. 2009; 
Walter, et al. 2009). In these 3 studies, 12 of 68 APL samples 
(18%) showed increased MYC copy number as a result of tri-
somy 8 or focal gain. Interestingly, one of these studies did 
identify rare cases of non-APL AML in which a nearby, long-
interspersed noncoding RNA at CCDC26 was gained with-
out  MYC,  implicating  this  locus  in  AML  pathogenesis 
(Radtke, et al. 2009). Collectively, the data suggest that other 
changes caused by +h8/+m15, such as increased TRIB1, 
PVT1, or CCDC26, may also impact leukemogenesis and that 
there may be cooperative effects among MYC and nearby genes. 
transformation, and therefore suggest that gain of h8/m15 is 
only one step on the path to APL. Our morphological studies 
and our examinations of clonality are consistent with the 
combination of PML-RAR + MYC acting as a powerful 
initiator of leukemia. Progression to mono- to oligoclonal 
APL is subsequently reflected as an arrest of differentiation at 
the promyelocyte stage and aggressive tissue dissemination. 
Retroviral insertional mutagenesis may have a role in coop-
eration in transformation and thereby selection for dominant 
clones. In leukemias arising in Myc haploinsufficient mice, 
increased karyotypic changes were apparent, and the recur-
rent gains of mouse chromosomes 8 and 10 and common loss 
of a sex chromosome could indicate selection for particular 
cooperative copy number changes in this context.
We found that three MYC alleles accelerated myeloid 
disease in the context of PML-RAR. The leukemias that 
arose in PML-RAR mice expressing any of the MYC al-
leles were all characterized by a predominantly promyelo-
cytic morphology, consistent with the central role of the 
PML-RAR fusion in determining the differentiation state 
of the leukemia. The predominant immunophenotype of the 
leukemias included moderate expression of Gr-1 and expres-
sion of both CD117 (Kit) and CD34. There was some het-
erogeneity of immunophenotype, but antigen expression 
patterns did not correlate with the different MYC alleles (un-
published data).
Transduction of control FVB/n bone marrow with the 
same MYC retroviral vectors resulted mainly in the develop-
ment of lymphoid disease, with some myeloid disease seen 
with the MYCT58A allele. These results are consistent with 
previous studies demonstrating the ability of MYC to induce 
both lymphoid and myeloid neoplasms (Adams et al., 1985; 
Felsher and Bishop, 1999a; Hemann et al., 2005; Luo et al., 
2005; Smith et al., 2006). Retroviral transduction studies of 
Hemann et al. (2005) and Luo et al. (2005) gave rise to pre– 
B cell lymphomas or AML, respectively. Differences in vector 
design used by Luo et al. (2005) that may explain the diver-
gent results include murine species origin, inclusion of exon 
1 translation start site, and expression levels. Our finding that 
the  more  highly  expressed  stable  MYC  allele,  MYCT58A, 
could initiate AML even in the absence of PMLRAR is 
compatible with the possibility that higher expression levels 
contribute to an AML phenotype.
Our studies of human APL and AML provide additional 
insight into the role of MYC gain and MYC levels in human 
myeloid leukemia. Interestingly, human APLs, whether or 
not they have trisomy 8, show increased MYC levels as com-
pared with normal human promyelocytes. The leukemia stem 
cell of APL has been suggested to be within the promyelo-
cytic population (Guibal et al., 2009; Wojiski et al., 2009), 
and hence increased MYC levels may be an integral part of 
transforming these normal precursors into self-renewing leu-
kemic cells. Numerous genetic changes may impact MYC 
expression, including activation of FLT3 (Li et al., 2007), a 
common event in human APL (Kiyoi et al., 1997; Yokota   
et al., 1997; Kottaridis et al., 2001; Yamamoto et al., 2001; JEM VOL. 207, November 22, 2010 
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(Truong et al., 2003). Transduced cells were washed, counted with trypan 
blue, and injected into the retro-orbital sinus of lethally (9 Gy) irradiated re-
cipient FVB/n mice or FVB/n CD45.2 congenic mice.
Pathological analysis. Blood was obtained from the retro-orbital sinus. 
White blood cell count, hemoglobin, and platelet count were measured with 
the Hemavet 950 cell counter (CDC Technologies). Blood smears and cy-
tospins of cell suspensions prepared from bone marrow and spleen cells were 
stained with Wright’s Giemsa stain. Tissues were initially fixed in a buffered 
formalin solution. Sternae were decalcified for 2–3 h before embedding (for-
mic acid 11% and formaldehyde 85%). Paraffin-embedded sections were 
stained with hematoxylin & eosin (H&E). Photographs were taken on a 
Nikon Eclipse 80i microscope with a Nikon Digital Sight camera using 
NIS-Elements F2.30 software at a resolution of 2560 × 1920. Using Adobe 
Photoshop CS2, images were resized and set at a resolution of 300 pixels/
inch, autocontrast was applied, and, in select cases, unsharp mask and/or 
variations:darken was used to improve image clarity.
DNA purification and Southern blot analysis. Cells from bone marrow 
and spleen were collected and lysed in DNA lysis solution (100 mM Tris-
HCl,  pH  8.0,  5  mM  EDTA,  pH  8.0,  200  mM  NaCl,  0.2%  SDS,  and   
100 µg/ml proteinase K). Genomic DNA was isolated using isopropanol 
precipitation followed by 70% EtOH wash and resuspension in ddH20.   
After restriction digestion with EcoRI, DNA fragments were separated by 
electrophoresis and immobilized onto a Nitran membrane. A probe of GFP 
was isolated from a sequence-verified MSCV-IRES-GFP vector and labeled 
with radioactive -dCTP using Rediprime II Random Prime Labeling Sys-
tem (GE Healthcare). DNA was hybridized with the radio-labeled probe   
in a solution (7% SDS, 0.5 M NaP, pH 7.2, 1 mM EDTA, and 1% BSA)   
at 60°C overnight, membrane was washed three times, and autoradiograph 
was performed.
Cytogenetic  analysis. Cytogenetic analysis was performed on fresh or 
cryopreserved spleen cells obtained at the time of development of leukemia. 
Short-term (24 h) cultures were initiated by incubating 1.0 × 106 cells/ml   
in MyeloCult M5300 (StemCell Technologies) with 5 µg/ml hydrocorti-
sone 21-hemisuccinate, 5% horse serum, 4% pokeweed mitogen spleen-
conditioned medium, 100 ng/ml stem cell factor, and 6 ng/ml IL-3 or in 
MyeloCult M5300 with 15% fetal calf serum, 10 ng/ml stem cell factor, 10% 
IL-3 conditioned medium (Karasuyama and Melchers, 1988), and 10% IL-6 
conditioned medium (Harris et al., 1992) at 37°C (5% CO2/95% air, hu-
midified atmosphere). Metaphase cell preparations and SKY analyses were 
performed as previously described (Le Beau et al., 2002).
Quantitative  PCR  analysis. Genomic DNA was isolated from spleen 
and/or bone marrow cells upon death of the animal. Quantitative PCR 
analyses were performed to determine gene copy number of the wild-type 
Myc gene, Pgk-hprt (representing the null allele), and 2-microglobulin (primer 
and probe sequences are available upon request). Copy number for Myc and 
Pgk-hprt was standardized to 2-microglobulin and compared with a reference 
curve generated using allelic ratios of Myc (ranging from 50–100% of alleles 
represented in the sample). Q-PCR values between 0.6 and 1.5 were 
scored as a copy number of 1, values between 1.6 and 2.5 were scored as   
2 copies, and values between 2.6 and 3.5 were scored as 3 copies. When 
both spleen and bone marrow from the same animal were assessed, the val-
ues were averaged.
Cell lysates and immunoblotting. Cells from bone marrow and spleen 
were collected and lysed in RIPA lysis buffer (containing 25 mM Tris.HCl, 
Hepes, pH 7.6, 150 mM NaCl, 1% Nonidet-P40, 1% sodium deoxycholate, 
0.1% SDS) supplemented with Halt Protease Inhibitor Cocktail (Thermo 
Fisher Scientific). Protein concentrations were determined using the Bio-
Rad BCA protein assay kit (Bio-Rad Laboratories). Proteins were separated 
on  7.5%  SDS–polyacrylamide  gels  and  transferred  to  PVDF  membranes 
(Millipore) and incubated with c-Myc antibody 1:500 (SC-764; Santa Cruz 
A role for additional genes further away from MYC on chro-
mosome 8, including genes for which mouse chromosome 
15 is not syntenic, is also possible.
Several lines of evidence have come together to support 
the hypothesis that modest changes in MYC level may influ-
ence malignant transformation. In addition to the current 
study, work by Murphy et al. (2008) demonstrated that a 
modest increase in MYC protein levels can increase develop-
ment of lung adenocarcinomas and a single-nucleotide poly-
morphism associated with increased risk for human colon 
cancer shows a long-range interaction with the MYC locus and 
has been speculated to influence MYC expression (Pomerantz   
et al., 2009).
Clinically, our results suggest that agents that target in-
creased MYC may be useful for the treatment of AML. Work 
with a dominant-negative MYC allele has shown the poten-
tial  of  MYC  inhibition  to  prevent  and  reverse  malignant 
transformation with reversible impacts on normal tissues 
(Soucek et al., 2008). Posttranscriptional control is an impor-
tant mechanism for regulating protein levels of cellular MYC 
and the related protein N-MYC; phosphorylation can cause 
MYC to be degraded (Sears, 2004; Yaari et al., 2005). Inhibi-
tors of phosphatidylinositol-3 kinase increase phosphoryla-
tion of N-Myc, and thereby cause protein degradation and 
tumor regression in a mouse model of N-Myc–driven neuro-
blastoma (Chesler et al., 2006). Similarly targeted anti-MYC 
therapies might prove useful in the treatment of AML.
MATERIALS AND METHODS
Plasmids. HA-tagged human MYC, MYCT58A, and MYCMBII in MSCV-
IRES-GFP have been previously described (Hemann et al., 2005; Herbst   
et al., 2005). All plasmids were sequence verified and sequences are available 
upon request.
Mice. Mice were bred and maintained at the University of California at San 
Francisco, and their care was in accordance with Institutional Animal Care 
and Use Committee guidelines. FVB/n mice were purchased from The 
Jackson Laboratory, and hMRP8d-PML-RARA mice have been previously 
described (Brown et al., 1997). PR+Myc+/ mice were generated by crossing 
our PML-RARA mice to mice that were heterozygous for the Myc allele   
c-mycORF/+ (FVB/n strain background; Trumpp et al., 2001). Mice were   
observed daily for signs of illness. When any abnormality was observed, mice 
were  subjected  to  a  brief  physical  examination.  Blood  was  obtained  on   
animals that showed signs of illness and also in selected animals to screen for 
unsuspected disease. Mice were sacrificed when moribund or when physical 
examination  and  blood  cell  counts  indicated  likely  rapid  progression   
of illness.
Cell culture. BOSC23 cells were maintained in DME supplemented with 
10% heat-inactivated FBS, 100 U/ml penicillin, and 100 µg/ml streptomy-
cin. Freshly harvested bone marrow cells were cultured in stem cell media 
containing  Myelocult  M5300  (StemCell  Technologies)  with  15%  FBS,   
IL-3–conditioned media (Karasuyama and Melchers, 1988), 0.4 mM gluta-
mine, 100 U/ml penicillin G, 100 µg/ml streptomycin, 10 ng/ml rIL-3,   
10 ng/ml IL-6, and 10 ng/ml stem cell factor.
Retroviral transduction and transplantation. BOSC23 cells were trans-
fected with retroviral constructs as previously described (Pear et al., 1993). 
Retroviral supernatants were collected and used to transduce bone marrow 
cells (850,000 cells per well in 24-well plates) as previously described 2592 Gain of MYC underlies recurrent trisomy in APL | Jones et al.
transgenic mice (not transduced with retroviruses and with two copies of the 
wild-type Myc allele). Fig. S1 shows the histology of bone marrow, spleen, 
and liver 5 wk after transplantation of control or PML-RAR bone marrow 
transduced with MIG or MYC retroviruses indicating initial effects of com-
bined PML-RAR + MYC. Fig. S2 shows that MYCT58A and MYCMBII 
mutants also cooperated with PML-RAR to impair myeloid maturation 
and to initiate leukemogenesis. Fig. S3 shows that human MYC is more 
highly expressed in human APL than in normal promyelocytes and that 
MYC is increased in human AML with trisomy 8 as compared with AML 
with a normal karyotype. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20091071/DC1.
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